地舒单抗治疗转移性去势抵抗性前列腺癌后低钙血症持续时间延长。
Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.
机构信息
Department of Endocrinology, Monash Health, Monash Medical Centre, Clayton, Australia.
出版信息
Bone. 2013 Aug;55(2):305-8. doi: 10.1016/j.bone.2013.04.012. Epub 2013 Apr 25.
PMID:23685544
Abstract
Prostate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26 days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function.
摘要
前列腺癌是癌症死亡的主要原因，常伴有广泛的骨转移。我们报告了两例转移性去势抵抗性前列腺癌患者在接受地舒单抗第一剂治疗后发生低钙血症的病例，其中第一例需要 26 天的静脉补钙治疗。这是首例肾功能正常的患者在接受地舒单抗治疗后发生长时间低钙血症的报告。
Zotero 插件